Expression of Inflammation Depending on the Stage of Cervical Cancer

• Published in: Medicina (Kaunas, Lithuania) Vol. 60; no. 3; p. 349
• Main Authors: Vitkauskaite, Agne, Urboniene, Daiva, Celiesiute, Joana, Jariene, Kristina, Paskauskas, Saulius, Vaitkiene, Daiva, Vitkauskiene, Astra
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 20-02-2024; MDPI
• Subjects: Biomarkers; Cellular biology; Cervical cancer; Cytokines; Development and progression; Disease; Female; Gynecology; Health aspects; Human papillomavirus; Humans; Inflammation; inflammatory markers; Interleukin-6; lipocalin-2; Lymphocytes; Medical prognosis; Medical research; Medicine, Experimental; Mortality; Obstetrics; Prognosis; Radiation therapy; Ratios; Regression analysis; stages of cervical cancer; TREM-1; Triggering Receptor Expressed on Myeloid Cells-1; Uterine Cervical Neoplasms; Women; Womens health; Lithuania; United States > US; TREM-1; inflammatory markers; stages of cervical cancer; lipocalin-2; cervical cancer; interleukin-6
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina60030349

Cervical cancer (CC) remains a major public health problem, ranking as the fourth most common cause of cancer incidence and mortality in women globally. The development of CC is believed to be closely related to chronic inflammation. Thus, we aimed to evaluate the expression of systemic inflammation in patients with CC and to determine the threshold prognostic value of the systemic inflammation markers for CC and its advanced stage.
182 participants were recruited: 94 histology-proven patient with CC and 88 healthy women with NILM confirmed by liquid-based cytology test. The pre-treatment serum concentrations of cytokines, including IFN-β, IFN-γ, IL-1β, IL-2, IL-6, IL-10, IL-12p70, LCN2, TREM-1, and TNF-α, were determined for all study patients.
The odds ratio (OR) of having IL-6 concentration >17.4 pg/mL in the CC group compared to control patients was 11.4 (95% CI: 4.897-26.684); that of having TREM-1 concentration >355.6 pg/mL was 5.9 (95% CI: 2.257-15.767); and that of having LCN2 concentration >23,721.5 pg/mL was 3.4 (95% CI: 1.455-8.166). The odds ratio (OR) of having IL-6 concentration >28.7 pg/mL in advanced-stage CC (III-IV stage) compared to early-stage CC (I-II stage) was 2.921 (95% CI: 1.06-8.045), and that of having LCN2 concentration >25,640.0 pg/mL was 4.815 (95% CI: 1.78-13.026).
The pre-treatment serum inflammation markers IL-6, TREM-1, and LCN2 at specified levels could be used as predictors of cervical cancer, and IL-6 and LCN2 as predictors of an increased chance of advanced-stage (III-IV stages) cervical cancer. Patients with cervical cancer had expressed systemic inflammation, and expression of inflammation elevated the chance of having CC and advanced-stage disease.